HDAC4 silencing has been proven to attenuate diabetic renal injury, which suggests that pharmacological inhibition of HDAC4 with isoform-selective inhibitor could be a therapeutic option in diabetic nephropathy [211] (Figure 5). This evidence concerns the gene HDAC4 and diabetic kidney disease.